Last reviewed: June 28, 2026 Last updated: June 28, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
A flow chart illustrating selection of the study cohort is shown in Fig
Biological actions of GLP-1, source: reference [1] Evolution of GLP1 GLP-1RAs Currently, there are nine GLP-1RAs approved for marketing worldwide (Table 1), mainly for the treatment of diabetes and obesity, of which tirzepatide is a novel dual GLP-1RA/GIPR agonist
Consent provided on one Brand Website does not automatically apply to other Brand Websites
Your prescriber will use whichever pathway matches your primary diagnosis
Nature 619 , 19 (2023)